The short answer
A specific increase in bleeding from curcumin with acalabrutinib has not been established. Have concentrated supplements reviewed because the cancer medicine itself can cause bleeding or low platelets.
What this answer covers
Oral acalabrutinib with curcumin products. Defined herbal preparations in aspirin studies are distinct from this cancer-drug pair. Turmeric contains multiple constituents and is not isolated curcumin.
- Supplement or preparation
- Curcumin
- Medication ingredient
- acalabrutinib
Check the prescribed treatment
This review concerns oral acalabrutinib used for selected blood cancers. CALQUENCE tablets use the maleate salt, while capsules contain the free-base form. The formulations have different acid-reducer instructions, so follow the product actually prescribed and keep the full treatment regimen intact.
The human trial was largely negative
A randomized study tested defined Panax ginseng and turmeric preparations alone and with aspirin in healthy volunteers. Overall clotting and platelet measures were not meaningfully worsened, and no significant bleeding was reported. Some individual platelet-assay responses occurred, so the findings should not be described as proving no biological effect.
The preparation and population limit the conclusion
The study tested turmeric preparations, not isolated curcumin. Different extracts and added ingredients may behave differently, but laboratory theories alone do not establish bleeding during acalabrutinib treatment. No exact combination trial was identified.
Use individualized precautions
Show the supplement and other medicines to the oncology team. Follow blood-count monitoring and report new bleeding or bruising promptly. Do not use the negative trial to override a low platelet count, and do not invent a dose gap or stop the cancer medicine yourself.
Evidence and practical considerations
Side effects & toxicity
The original bleeding claim is insufficient; a human trial with another drug was largely negative and does not establish target-pair safety.
- Exact scope
- Oral acalabrutinib with curcumin products. Defined herbal preparations in aspirin studies are distinct from this cancer-drug pair. Turmeric contains multiple constituents and is not isolated curcumin. with RxNorm 1986808 IN acalabrutinib. Exact current oral product: CALQUENCE oral acalabrutinib maleate tablets. Salt, formulation and regimen distinctions explicit.
- Medication form and route
- Oral
What remains uncertain
- No exact combination outcome study; different-drug healthy-volunteer null retained. Isolated curcumin identity is not established by a turmeric-product trial.
Factors that may matter: Exact oral formulation and supplement preparation; Drug exposure versus clinical outcomes; Dose and duration; Platelet count and neurological symptoms.
Read the supporting source summaries
Source 1: Current original prescribing information
dailymed.nlm.nih.gov · Source check Sep 11, 2026
Population: Patients prescribed the exact oral formulation.
Bleeding/low platelet warnings; CYP3A induction may lower exposure; maleate-tablet PPI null differs from capsule restriction.
How this applies: RxNorm 1986808 IN acalabrutinib. Exact current oral product: CALQUENCE oral acalabrutinib maleate tablets. Salt, formulation and regimen distinctions explicit.
Exact product source, not a direct study of every supplement. Population, active metabolites and formulation scope retained.
Source 2: Original clinical research
pubmed.ncbi.nlm.nih.gov · Source check Sep 11, 2026
Population: 25 healthy volunteers allocated for each herbal preparation.
No clinically relevant overall platelet/coagulation effect or significant bleeding; occasional individual arachidonic-acid assay responses.
How this applies: Exact preparation/population/endpoints only; applicability to acalabrutinib independently assessed.
Abstract-only exact formulations not fully characterized here. Different drug/population; turmeric is not isolated curcumin and P. ginseng is not American ginseng.
Source 3: Medication terminology
rxnav.nlm.nih.gov · Source check Sep 11, 2026
Population: Terminology.
acalabrutinib is IN.
How this applies: Exact ingredient.
Not clinical evidence.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Research summary published | |
| Article prepared | |
| Sources checked and article drafted. |
Article revision: f4b1da144eb9a1d3
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.